Skip to main content

Table 1 The extent of metastases and history of chemotherapy in ten patients with prostate cancer

From: Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Number Age (y/o) Metastases History of CTx Dose GBq
1 70 Bone3, Ln1, LR No 5.8
2 77 Bone3, LR Yes 6.1
3 67 Bone3, Ln1, LR Yes 6.0
4 75 Bone3, Ln1 No 5.9
5 77 Bone3, Ln2 No 4.1
6 81 Bone3, Ln1 No 5.9
7 62 Ln2 Yes 5.8
8 74 Ln2, liver met Yes 5.7
9 76 Bone1, Ln1, Yes 5.8
10 76 Bone3, Ln1 No 5.2
  1. Bone1 <6 bone metastases, bone2 6–20 bone metastases, bone3 >20 bone metastases
  2. Ln1 lymph node metastasis (abdominal, iliacal and inguinal), Ln2 Ln1 + thoracal lymph node metastasis, LR local recurrence, CTx chemotherapy